                         SEQUENCE LISTING

<110>  Sana Biotechnology, Inc.
 
<120>  METHODS OF TREATING SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC 
       CELLS, AND ASSOCIATED METHODS AND COMPOSITIONS

<130>  122864-01-5044

<150>  63/065,342
<151>  2020-08-13

<150>  63/136,137
<151>  2021-01-11

<150>  63/151,628
<151>  2021-02-19

<150>  63/175,030
<151>  2012-04-14

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for ABO

<400>  1
ucucuccaug ugcaguagga                                                   20


<210>  2
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for FUT1

<400>  2
cuggaugucg gaggaguacg                                                   20


<210>  3
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for RH

<400>  3
gucuccggaa acucgaggug                                                   20


<210>  4
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for F3 (CD142)

<400>  4
acaguguaga cuugauugac                                                   20


<210>  5
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for B2M

<400>  5
cgugaguaaa ccugaaucuu                                                   20


<210>  6
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for CIITA

<400>  6
gauauuggca uaagccuccc                                                   20


<210>  7
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence for TRAC

<400>  7
agagucucuc agcugguaca                                                   20


<210>  8
<211>  20
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence 20-mer


<220>
<221>  misc_feature
<223>  n can be any ribonucleotide base

<220>
<221>  misc_feature
<222>  (1)..(20)
<223>  n is a, c, g, or u

<400>  8
nnnnnnnnnn nnnnnnnnnn                                                   20


<210>  9
<211>  12
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic 12 nt crRNA repeat sequence

<400>  9
guuuuagagc ua                                                           12


<210>  10

<400>  10
000

<210>  11
<211>  99
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  synthetic guide sequence


<220>
<221>  misc_feature
<223>  n can be any ribonucleotide base

<220>
<221>  misc_feature
<222>  (1)..(20)
<223>  n is a, c, g, or u

<400>  11
nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc       60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuu                              99


<210>  12
<211>  305
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic human CD47 polypeptide

<400>  12

Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe Cys Asn 
1               5                   10                  15      


Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala Gln Asn 
            20                  25                  30          


Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp Ile Tyr 
        35                  40                  45              


Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp Phe Ser 
    50                  55                  60                  


Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala Ser Leu 
65                  70                  75                  80  


Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr Thr Cys 
                85                  90                  95      


Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu Leu Lys 
            100                 105                 110         


Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu Ile Val 
        115                 120                 125             


Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe Gly Ile 
    130                 135                 140                 


Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr Ile Ala 
145                 150                 155                 160 


Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val Gly Ala 
                165                 170                 175     


Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr Gly Leu 
            180                 185                 190         


Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His Tyr Tyr 
        195                 200                 205             


Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala Ile Leu 
    210                 215                 220                 


Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu Ser Leu 
225                 230                 235                 240 


Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile Ser Gly 
                245                 250                 255     


Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr Met Lys 
            260                 265                 270         


Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys Ala Val 
        275                 280                 285             


Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met Asn Asp 
    290                 295                 300                 


Glu 
305 


<210>  13
<211>  323
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic human CD47 polypeptide with signal sequence

<400>  13

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly 
1               5                   10                  15      


Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe 
            20                  25                  30          


Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala 
        35                  40                  45              


Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp 
    50                  55                  60                  


Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp 
65                  70                  75                  80  


Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala 
                85                  90                  95      


Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr 
            100                 105                 110         


Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu 
        115                 120                 125             


Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu 
    130                 135                 140                 


Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe 
145                 150                 155                 160 


Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr 
                165                 170                 175     


Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val 
            180                 185                 190         


Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr 
        195                 200                 205             


Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His 
    210                 215                 220                 


Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala 
225                 230                 235                 240 


Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu 
                245                 250                 255     


Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile 
            260                 265                 270         


Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr 
        275                 280                 285             


Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys 
    290                 295                 300                 


Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met 
305                 310                 315                 320 


Asn Asp Glu 
            


<210>  14
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic Whitlow linker

<400>  14

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 
1               5                   10                  15      


Lys Gly 
        


